DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
All 50 states tracked. 14 cover weight-loss GLP‑1s with PA, 23 require PA evidence, 13 exclude weight-loss indication. Diabetes coverage is standard nationwide.
Source: KFF — Medicaid Coverage of and Spending on GLP-1s. The state list below reflects our last editorial review; where it differs from this January 2026 update, treat the KFF figures as current and confirm with your state Medicaid office before you fill.
State Medicaid covers FDA-approved weight-loss GLP-1s (Wegovy, Zepbound) for eligible patients.
Coverage available with prior authorization. Documentation of BMI, comorbidity, and prior weight-loss efforts typically required.
State Medicaid does not cover weight-loss-only indications. Type 2 diabetes coverage may still apply for Ozempic and Mounjaro.
Editorial summary, not legal or medical advice. State Medicaid policies change frequently. Confirm with your prescriber or your state Medicaid member services before relying on any single source.